High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis
AssigneeBiosite, Inc.
InventorsJoe Buechler, Kevin Nakamura
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for measuring secretagogin in test samples, particularly patient samples. Preferred methods comprise performing a sandwich immunoassay, most preferably using a pair of monoclonal antibodies that bind to secretagogin.
Claims39
An immunoassay method for detection of secretagogin in a test sample, comprising:
- contacting a test sample obtained from a subject with a first monoclonal antibody that binds secretagogin and with a second monoclonal antibody that binds secretagogin, wherein said first and second monoclonal antibodies form a complex with secretagogin if present;
- generating a signal indicative of said complex formation;
- and
- relating the signal to the presence or amount of secretagogin in the test sample.
A method of detecting or prognosing glioma or adenocarcinoma in a patient, comprising:
- providing a sample form a patient having or suspected of having cancer;
- contacting the sample with an antibody to determine the level of secretagogin in the patient, wherein a level of secretagogin lower than the level in control patients is an indication of presence of cancer, and the lower the level of secretagogin in the patient relative to the level in control patients, the worse the prognosis of the patient.
27-50. (canceled)
An isolated antibody or fragment thereof that competes with a monoclonal antibody comprising a heavy chain variable region of SEQ ID NO:2 and a light chain variable region of SEQ ID NO:3, or a monoclonal antibody comprising a heavy chain variable region of SEQ ID NO:4 and a light chain variable region of SEQ ID NO:5.
Dependencies are inferred from the claim text.